[New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
Nawroth
P
P
Abteilung Innere Medizin 1, Medizinische Klinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany.
D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000191:economics*; D017277:Drug Approval / Q000191:economics*; D016527:Drug Costs / Q000706:statistics & numerical data*; D004345:Drug Industry / Q000191:economics; D019317:Evidence-Based Medicine; D015444:Exercise; D005858:Germany; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D008019:Life Style; D009313:National Health Programs / Q000191:economics*; D011379:Prognosis; D011785:Quality Assurance, Health Care / Q000191:economics
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human